2seventy bio Inc (TSVT) News

2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences

2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference...

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will present at the following upcoming investor...

Form 8-K - Current report

Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that a notice was published in the Federal Register that...

Form 8-K/A - Current report: [Amend]

Biotech Shares Soar Premarket On Sale Of R&D Assets

A Massachusetts-based biotech company is stealing the show so far during Tuesday’s premarket hours after it was announced that the company...

Form 8-K - Current report

2seventy bio Announces New Strategic Path Forward

- Company to focus exclusively on commercialization and development of Abecma, in partnership with Bristol Myers Squibb - - Company to sell...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8...

2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call...

2seventy bio Reiterates Commitment to Maximizing Shareholder Value

2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following...

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]